Biotech Values

[biopearl]

acgood, Interesting that almost a third of the presentation devoted to Lovonox/Copaxone issues. Clearly TEVA feels the heat. Regarding "life cycle issues" I think he meant "life style" issues--a bissle lost in translation there. Re FDA and lovonox, although it has been mentioned before on this board, CFO said current issues relate to evaluation regarding immunogenicity and are underway at a different part of the FDA from the generic approval part. If the current ASH presentations give us any insight, then as Dew and others have pointed out TEVA may not come up clean in this part of the product evaluation. Waiting with interest...bp